Teva Considering Cutting up to 10,000 Jobs: Bloomberg
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - BNN Bloomberg
Teva Loses CEO, Leaving Investors to Guess What's Next - Bloomberg
A bottle of Teva Pharmaceutical Industries Ltd. Clonazepam medication... News Photo - Getty Images
Future Teva CEO Seeks to 'Formulate Clear Strategy' - YouTube
Teva makes $40B offer for Mylan
Activist Investor Jana Partners Takes Stake in Teva, Report Says | Ctech
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
Teva's $4 Billion Medicine Faces Patent Judgment Day in U.S. - Bloomberg
Teva CEO to Meet Netanyahu With Blunt Message on Need for Cuts - Bloomberg
Teva CEO Calls 'Trough' Revenues Consequence of Patent Expirations - YouTube
ADHD Drug Adderall Supply Delays Likely to Continue for 2-3 Months, Teva Says - Bloomberg
Teva plans to raise Mylan bid by as much as $2 billion: Bloomberg | Reuters
Drugmaker Teva makes $40B bid for rival Mylan
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - Bloomberg
Actavis CEO: Teva-Mylan deal could be "value-destroying" - גלובס
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Sandoz, Amneal and Rhodes join Teva in nationwide generic Adderall shortage as demand spikes
Teva Analysts Say Migraine Drug Approval Gives Needed Relief - Bloomberg
Adderall Shortages Spread to 4 Pharmaceutical Companies Including Teva, Novartis - Bloomberg
Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Tags search | Ctech
The Difficulties of Cloning a CEO - Bloomberg
Teva flags supply constraints to ADHD drug Adderall as demand rises (NYSE: TEVA) | Seeking Alpha
